Dan Zhi Xiao
Yao Wan and its Constituent Herbs on Antioxidant Activity and Inhibition of
Nitric Oxide Production
Liao H, et al. Centre for Phytochemistry and Pharmacology,
Southern Cross University, Lismore NSW 2480, Australia and Shanxi Provincial
People's Hospital, Taiyuan, Shanxi 030012, China
Dan Zhi Xiao Yao Wan (DW) is a common 10 herbs formulation in China for
regulating several clinical conditions affecting women. This research tried to
explain one of DW's functions, purging heat, using in vitro pharmacological
analyses. The whole formulation and each single herb of DW were compared based
on antioxidant activity with the oxygen radical absorbance capacity (ORAC)
assay, and for their inhibitory effect (IE) on nitric oxide (NO) production by
lipopolysaccharide (LPS)-activated RAW 264.7 macrophages with the Griess assay.
The results showed that DW as a whole formulation had both antioxidant activity
and an IE on NO production, while the individual herb component of DW varied in
their ORAC values and inhibition of NO production. The ORAC value of the whole
DW was 450 mumol TE g(-1). The order of antioxidant (ORAC) activity of the
single herbs was: Mentha haplocalyx (1352 mumol TE g(-1)) > Glycyrrhiza
uralensis (1184 mumol TE g(-1)) > Gardenia jasminoides (1129 mumol TE g(-1)) >
Paeonia suffruticosa (465 mumol TE g(-1)), with the contributions being additive
rather than synergistic. The production of nitrite by stimulated RAW 264.7
murine macrophages (unstimulated: 0.5 +/- 0.1 muM versus LPS: 38.9 +/- 2.3 muM)
was significantly inhibited (P < 0.05) by M. haplocalyx, G. jasminoides,
Bupleurum chinense and Paeonia lactiflora. DW as a whole had an IE on NO
production, but this was not significant. The single herb M. haplocalyx had the
highest ORAC value and the highest IE on NO production, followed by G.
jasminoides. Both of these herbs have the 'purging heat' property in the theory
of traditional Chinese medicine and this property of the samples may be
correlated with the antioxidant activity and IE on NO production.
Evid Based Complement Alternat Med. 2007 Dec;4(4):425-30.
and Controlled Clinical Study of Modified Prescriptions of Simiao Pill In the
Treatment of Acute Gouty Arthritis
Shi XD, et al. China Academy of Chinese Medical Sciences,
Beijing, (100700), China, email@example.com.
Objective: To investigate the compatibility of a modified prescription of Simiao
Pill () in the treatment of acute gouty arthritis and to verify the clinical
efficacy and safety of the drug through a clinical trial. Methods: A randomized
and controlled clinical trial was designed based on clinical epidemiological
principles. A total of 07 patients with acute gouty arthritis were enrolled and
randomly assigned to four groups. The first group (Group I) included 7 patients
taking gout prescription II; the second group (Group II) included 27 patients
taking gout prescription II; the third group (Group III) included 28 patients
taking gout prescription III; and the fourth group (control group) included
patients taking indomethacin and Benzobromarone as a control group. The duration
of the treatment in all groups was two weeks. After the treatment, the index of
blood uric acid, blood leukocyte count, score of clinical symptoms, etc. were
observed and measured. Results: The total clinical effective rate of the three
different modified prescriptions of the Simiao Pill was above 96%, significantly
superior to that of the control group (68%, P<0.05). In terms of the improvement
of main symptoms, the scores of four symptoms in all TCM treatment and control
groups decreased after treatment, with statistically significant differences
(P<0.0 ). Moreover, the scores markedly fell more so in the three Chinese herb
groups than in the control group, and especially in Group III (P<0.05). There
was a statistically significant difference in blood uric acid values before and
after the treatment in the same group but no significant inter-group difference
was seen. Conclusion: The modified prescriptions, based on the clinical
research, clinical experience and traditional Chinese medicine theory, did show
a better effect than Western medicine in this clinical study. Moreover, the
prescriptions were precise, with the herbs inexpensive and readily available.
The patients had good compliance with less adverse reactions noted. The modified
prescription has a favorable prospect for future development and is worthy of
further blind trials with larger samples.
Chin J Integr Med. 2008 Jan 25
Xuanzhong (GB 39) and Ashi Points for Treatment of Orthopedic Postoperative Pain
Sun ZH, et al. Section of Acupuncture, The Third Affiliated
Hospital of Luohe Medical Higher Training School, Henan 462002, China.
OBJECTIVE: To compare the therapeutic effects between
acupuncture and Bezoxazocine injection in treatment of orthopedic postoperative
pain. METHODS: Sixty patients were randomly divided into an acupuncture group
and a medication group, 30 cases in each group. The patients in the acupuncture
group were treated by acupuncture at Xuanzhong (GB 39) as main point and Ashi
points for 30 minutes; the medication group were treated by intramuscular
injection of Bezoxazocine injection, 20 mg once, three times per day. Then the
pain changes within 48 hours were observed and recorded in two groups. RESULTS:
The good rates at 24 hours and 48 hours were 89.2% and 100.0% in the acupuncture
group and 81.4% and 96.3% in the medication group, respectively. The analgesic
effect of acupuncture was better than that of Bezoxazocine injection (P < 0.05).
CONCLUSION: Analgesic effect of acupuncture at Xuanzhong (GB 39) on orthopedic
postoperative pain and Ashi points is better than Bezoxazocine injection.
Zhongguo Zhen Jiu. 2007 Dec;27(12):895-7